Literature DB >> 7140142

Quazepam and flurazepam: long-term use and extended withdrawal.

A Kales, E O Bixler, C R Soldatos, A Vela-Bueno, J Jacoby, J D Kales.   

Abstract

Two investigation benzodiazepine hypnotics with long half-lifes, (30 and 15 mg quazepam and 30 mg flurazepam) were evaluated in 47-night sleep laboratory studies. The effectiveness and side effects of these benzodiazepines were assessed during short-, intermediate-, and long-term use. Subjects were also assessed for presence of rebound insomnia during the 15 days following abrupt withdrawal. Quazepam, 15 and 30 mg, and flurazepam, 30 mg, each were effective in sleep induction and maintenance after short- and intermediate-term use. Some loss of effectiveness was noted during long-term use of both doses of quazepam and, to a lesser extent, of flurazepam. Subjective reports of improvement in sleep latency and total sleep time were in general agreement with the objective data. During the 15 nights after abrupt withdrawal of these two long-half-life drugs there was no rebound insomnia, either immediate or delayed. Both drugs exerted carry-over effectiveness on the first 2 to 3 nights after withdrawal; with quazepam this effect persisted throughout the withdrawal period. Quazepam, 30 mg, induced frequent side effects related to sleepiness. Side effects noted with 30 mg flurazepam were less frequent and severe, while the side effects with 15 mg quazepam were minimal. These data suggest that the optimal dose of quazepam is 15 mg.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7140142     DOI: 10.1038/clpt.1982.236

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

1.  Rebound insomnia in normals and patients with insomnia after abrupt and tapered discontinuation.

Authors:  T Roehrs; L Merlotti; F Zorick; T Roth
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Hypnotics in the elderly. What cause for concern?

Authors:  K Morgan
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

3.  Withdrawal regimen for triazolam-dependent patients.

Authors:  J A Fleming; K Rungta; T Isomura; M J McMillan
Journal:  CMAJ       Date:  1986-06-01       Impact factor: 8.262

4.  Effects of lormetazepam and of flurazepam on sleep.

Authors:  K Adam; I Oswald
Journal:  Br J Clin Pharmacol       Date:  1984-05       Impact factor: 4.335

5.  Meta-analysis of benzodiazepine use in the treatment of insomnia.

Authors:  A M Holbrook; R Crowther; A Lotter; C Cheng; D King
Journal:  CMAJ       Date:  2000-01-25       Impact factor: 8.262

Review 6.  Rebound insomnia and newer hypnotics.

Authors:  M Lader
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

7.  Comparison of the effects of quazepam and triazolam on cognitive-neuromotor performance.

Authors:  A M Nikaido; E H Ellinwood
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

8.  Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care.

Authors:  Joseph A Lieberman
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 9.  Quazepam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia.

Authors:  S I Ankier; K L Goa
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

10.  Overestimations of hypnotic drug effects by insomniacs--a hypothesis.

Authors:  D Schneider-Helmert
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.